124 related articles for article (PubMed ID: 6469505)
1. The key role of hydroxylation for the cytostatic activity and selectivity of cyclophosphamide.
Hilgard P; Brock N
Invest New Drugs; 1984; 2(2):131-2. PubMed ID: 6469505
[TBL] [Abstract][Full Text] [Related]
2. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.
Niemeyer U; Engel J; Scheffler G; Molge K; Sauerbier D; Weigert W
Invest New Drugs; 1984; 2(2):133-9. PubMed ID: 6469506
[TBL] [Abstract][Full Text] [Related]
3. [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
Sloderbach A; Górska A; Sikorska M; Misiura K; Hładoń B
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1235-53. PubMed ID: 24379264
[TBL] [Abstract][Full Text] [Related]
4. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Chang TK; Weber GF; Crespi CL; Waxman DJ
Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
[TBL] [Abstract][Full Text] [Related]
5. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
Hohorst HJ; Draeger U; Peter G; Voelcker G
Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
[TBL] [Abstract][Full Text] [Related]
6. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J; Küpker F; Blaschke G; Jürgens H
Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
Chang TK; Yu L; Maurel P; Waxman DJ
Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
[TBL] [Abstract][Full Text] [Related]
8. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Lelieveld P; van Putten LM
Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
[TBL] [Abstract][Full Text] [Related]
9. The enzymatic basis of cyclophosphamide specificity.
Hohorst HJ; Bielicki L; Voelcker G
Adv Enzyme Regul; 1986; 25():99-122. PubMed ID: 3028054
[TBL] [Abstract][Full Text] [Related]
10. Mixed function oxidase activities of established human colon carcinoma cell lines in the activation of cyclophosphamide.
Moskwa PS; Vadi H; Drewinko B
Cancer Res; 1985 Nov; 45(11 Pt 1):5447-51. PubMed ID: 4053018
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide).
Alberts DS; Einspahr JG; Struck R; Bignami G; Young L; Surwit EA; Salmon SE
Invest New Drugs; 1984; 2(2):141-8. PubMed ID: 6469507
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
14. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
Blomgren H; Hallström M
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
[TBL] [Abstract][Full Text] [Related]
15. Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study.
Dabbish E; Scoditti S; Shehata MNI; Ritacco I; Ibrahim MAA; Shoeib T; Sicilia E
J Comput Chem; 2024 Apr; 45(10):663-670. PubMed ID: 38088485
[TBL] [Abstract][Full Text] [Related]
16. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.
Yu L; Waxman DJ
Drug Metab Dispos; 1996 Nov; 24(11):1254-62. PubMed ID: 8937861
[TBL] [Abstract][Full Text] [Related]
17. [Effective levels of cyclophosphamide and metabolites in pleural effusions during intravenous therapy (author's transl)].
Wagner T; Heydrich D
Arzneimittelforschung; 1982; 32(5):566-8. PubMed ID: 7201835
[TBL] [Abstract][Full Text] [Related]
18. Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.
Brock N
J Cancer Res Clin Oncol; 1986; 111(1):1-12. PubMed ID: 3949846
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors.
Atassi G; Hilgard P; Pohl J
Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511
[TBL] [Abstract][Full Text] [Related]
20. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
